Press releases

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children – - Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - BOSTON --(BUSINESS WIRE)--Oct. 9, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)

BOSTON --(BUSINESS WIRE)--Oct. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD and type 2 diabetes, treatment with inaxaplin led to a reduction in UACR of -17.3% at Week 13

- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - BOSTON --(BUSINESS WIRE)--Sep. 15, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier

Crinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a planned transition, Jonathan Poole, current SVP Finance, will be appointed EVP, CFO,

BOSTON --(BUSINESS WIRE)--Aug. 26, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will

— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire

BOSTON --(BUSINESS WIRE)--Jul. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY ®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older - - Data simultaneously

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - -